Our Mission & Vision
To transform clinical care through cutting-edge clinical research.
Our Mission & Vision
To transform clinical care through cutting-edge clinical research in respiratory health.
Who We Are
PulmonIx is an award-winning clinical research site specializing in COPD, Asthma, Pulmonary Fibrosis, and other serious lung diseases. Our mission is simple yet powerful — to advance medical knowledge and improve patient livesthrough innovative, high-quality clinical trials.
Our Expertise
We conduct a wide range of studies in pulmonary and critical care medicine, with a strong focus on:
COPD
Asthma
Pulmonary Fibrosis (PF)
Respiratory viruses
Septic shock
PulmonIx offers one of the largest selections of Pulmonary Fibrosis trials in North Carolina, providing patients with early access to promising new therapies before they become widely available.
Our Legacy
Our commitment to excellence began with the Piedmont Respiratory Research Foundation (PRRF), founded by Dr. Patrick Wright in the early 2000s. Building on that strong foundation, Dr. Murali Ramaswamy launched PulmonIx, LLC in 2015 to expand our reach and impact in respiratory research.
Our Team
Led by Drs. Ramaswamy and Wright — both Certified Principal Investigators (CPI) through the Association of Clinical Research Professionals (ACRP) — our investigators and coordinators combine scientific precision with compassionate patient care. We have the infrastructure, expertise, and dedication required to ensure the success of every trial we conduct.
Our Partnerships & Recognition
We proudly partner with the LeBauer HealthCare Pulmonary and Critical Care Division of Cone Health and are recognized by the Pulmonary Fibrosis Foundation (PFF) as an official Care Center. We also conducted the first Phase 1 study in Cone Health’s history, a milestone achievement that reflects our commitment to innovation and excellence.
Our Impact
Our research has contributed to novel drug approvals, landmark publications, and advancements in respiratory care— giving hope, options, and better outcomes to patients facing serious lung conditions.